Cns Pharmaceuticals Inc
Research Cns Pharmaceuticals Inc (CNSP) on Bullrun: market cap USD 8.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCNSP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.48M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 4.94M
- Free cash flow-USD 4.65M
Valuation Snapshot
latest market cap is USD 8.48M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 15.85M | -USD 13.83M | n/a | -35.75 | USD 7.20M | USD 328.57K | USD 4.52M |
| FY2024 | USD 0 | -USD 14.86M | -USD 17.12M | n/a | -466.89 | USD 6.46M | USD 326.07K | USD 6.18M |
| FY2023 | n/a | -USD 18.85M | -USD 14.14M | n/a | -12509.11 | USD 548.72K | USD 300.81K | -USD 4.43M |
| FY2022 | n/a | -USD 15.27M | -USD 10.56M | n/a | -11.22 | USD 10.06M | USD 449.87K | USD 8.13M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.48M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.32M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.48M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.62M | n/a | n/a | n/a |
About Cns Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cns Pharmaceuticals Inc's market cap?
Cns Pharmaceuticals Inc's market capitalization is USD 8.48M.
What does Cns Pharmaceuticals Inc do?
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.